Related Experiment Videos
[Glucose tolerance in adrenocortical hyperfunction. Analysis of 100 cases]
J Krassowski1, M Godziejewska, J Kurta
1Kliniki Endokrynologii CMKP w Warszawie.
Polskie Archiwum Medycyny Wewnetrznej
|July 1, 1994
Summary
Glucocorticoid excess from adrenocortical hyperfunction frequently impairs glucose tolerance, leading to diabetes in many patients. Glucose tolerance did not correlate with hormonal levels, age, or obesity in this study.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Clinical Medicine
Context:
- Adrenocortical hyperfunction, including Cushing's disease and syndrome, involves excessive cortisol production.
- Hypercortisolism is known to affect glucose metabolism.
- Understanding the relationship between adrenocortical hyperfunction and glucose tolerance is crucial for patient management.
Purpose:
- To assess glucose tolerance in patients with adrenocortical hyperfunction.
- To determine the prevalence of diabetes and impaired glucose tolerance in this population.
- To investigate correlations between glucose tolerance and clinical/hormonal parameters.
Summary:
- Glucose tolerance was evaluated in 100 patients with adrenocortical hyperfunction (79 with Cushing's disease, 21 with Cushing's syndrome).
- Overt diabetes was diagnosed in 19 patients, while an additional 21 patients were diagnosed with diabetes after tolerance testing, and 23 showed impaired glucose tolerance.
- Glucose tolerance, measured by 60 and 120-minute glucose levels, did not correlate with hormonal markers of hyperfunction, patient age, or obesity levels.
Impact:
- This study highlights the significant impact of glucocorticoid excess on glucose metabolism, underscoring the high prevalence of glucose intolerance and diabetes in adrenocortical hyperfunction.
- The findings suggest a complex mechanism underlying glucocorticoid-induced glucose dysregulation, independent of common influencing factors like age and obesity.
- Further research into the intricate mechanisms is warranted to improve diagnostic and therapeutic strategies for managing metabolic complications in these patients.